You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Demographic characteristics: ATP immunogenicity cohorts at Day 21 in both studies

From: Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

Characteristic Categories Study in adults Study in children
   Q-Pan D-Pan Q-Pan0.9 D-Pan0.9 Q-Pan1.9
N   164 164 76 75 58
Age (years) Mean (SD) 39.7 (11.98) 40.1 (11.74) 6.0 (2.03) 6.0 (2.02) 6.0 (2.00)
Range 18-60 19-60 3-9 3-9 3-9
Gendern (%) Female 75 (45.7) 86 (52.4) 30 (39.5) 38 (50.7) 27 (46.6)
Male 89 (54.3) 78 (47.6) 46 (60.5) 37 (49.3) 31 (53.4)
Racen (%) African/African American 3 (1.8) 2 (1.2) 0 0 0
Central/South/East & Southeast Asian 0 0 76 (100) 75 (100) 56 (100)
Arabic/North African 3 (1.8) 0 0 0 0
  Caucasian/European 158 (96.3) 162 (98.8) 0 0 0
  1. N number in the specified cohort, n (%) number (percentage), SD standard deviation. See Table 1 for details of treatment groups in each study.